Upfront Allogeneic Blood Stem Cell Transplantation for Patients with High-Risk Myelodysplastic Syndromeor Secondary Acute Myeloid Leukemia Usinga FLAMSA-Based High-Dose Sequential Conditioning Regimen

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 3, 2012, Pages 466-472

  Saure, Christian ^a   Schroeder, Thomas ^a   Zohren, Fabian ^a   Groten, Anke ^a   Bruns, Ingmar ^a   Czibere, Akos ^a   Galonska, Lars ^a   Kondakci, Mustafa ^a   Weigelt, Christian ^a   Fenk, Roland ^a   Germing, Ulrich ^a   Haas, Rainer ^a   Kobbe, Guido ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Anti CD25 monoclonal antibody; Graft versus host disease; Interleukin 2 receptor antagonists; Peripheral blood stem cell transplantation; Unrelated donor

Indexed keywords

AMSACRINE; BASILIXIMAB; CD34 ANTIGEN; CORTICOSTEROID; CYTARABINE; ETANERCEPT; FLUDARABINE; INFLIXIMAB; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ADULT; AGE DISTRIBUTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; BACTERIAL PNEUMONIA; CANCER MORTALITY; CENTRAL NERVOUS SYSTEM; CHLAMYDIAL PNEUMONIA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS PNEUMONIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PROSPECTIVE STUDY; PYREXIA IDIOPATHICA; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT; VEIN OCCLUSION;

ADULT; AGED; AMSACRINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MELPHALAN; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS; VIDARABINE;

EID: 84856975947     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.09.006     Document Type: Article

References (39)

1. Oliansky D.M., Antin J.H., Bennet J.M., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant 2009, 15:137-172.
2. Lodewyck T., Cornelissen J.J. Allogeneic stem cell transplantation in acute myeloid leukemia: a risk-adapted approach. Blood Rev 2008, 22:293-302.
3. Gratwohl A., Baldomero H., Passweg J., et al. Hematopoietic stem cell transplantation for hematological malignancies in Europe. Leukemia 2003, 17:941-959.
4. Witherspoon R.P., Deeg H.J., Storer B., Anasetti C., Storb R., Appelbaum F.R. Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol 2001, 19:2134-2141.
5. Zittoun R.A., Mandelli F., Willemze R., de Witte T., Labar B., Resegotti L. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995, 332:217-223.
6. De Witte T., Hagemeijer A., Suciu S., et al. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica 2010, 95:1754-1761.
7. Cutler C.S., Lee S.J., Greenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004, 104:579-585.
8. Kindwall-Keller T., Isola L.M. The evolution of hematopoietic SCT in myelodysplastic syndrome. Bone Marrow Transplant 2009, 43:597-609.
9. Anderson J.E., Gooley T.A., Schoch G., et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997, 89:2578-2585.
10. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990, 76:1867-1871.
11. Deeg H.J., Appelbaum F.R. Hematopoietic stem cell transplantation for myelodysplastic syndrome. Curr Opin Oncol 2000, 12:116-120.
12. De Witte T., Hermans J., Vossen J., et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukemias: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000, 110:620-630.
13. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hematopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002, 100:1201-1207.
14. Sierra J., Perez W.S., Rozman C., et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002, 100:1997-2004.
15. De Witte T., Oosterveld M., Span B., Muus P., Schattenberg A. Stem cell transplantation for leukemias following myelodysplastic syndromes or secondary to cytotoxic therapy. Rev Clin Exp Hematol 2002, 6:72-85.
16. Pedersen-Bjergaard J., Philip P., Larsen S.O., Jensen G., Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 1990, 76:1083-1091.
17. Ballen K.K., Antin J.H. Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syndromes. Hematol Oncol Clin North Am 1993, 7:477-493.
18. Scott B.L., Storer B., Loken M.R., Storb R., Appelbaum F.R., Deeg H.J. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 2005, 11:65-73.
19. Nakai N., Kanda Y., Fukuhara S., et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 2005, 19:396-401.
20. Schmid C., Schleuning M., Hentrich M., et al. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant 2008, 41:721-727.
21. Schmid C., Schleuning M., Schwerdtfeger R., et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006, 108:1092-1099.
22. Schmid C., Schleuning M., Ledderose G., Tischer J., Kolb H.J. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005, 23:5675-5687.
23. Sperr W.R., Wimazal F., Kundi M., et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a score datatest of 419 patients of the Austrian MDS Study Group. Ann Oncol 2010, 116:2372-2381.
24. Boehm A., Sperr W.R., Leitner G., et al. Comorbidity predicts survival in myelodysplatic syndromes or secondary acute myeloid leukemia after allogeneic stem cell transplantation. Eur J Clin Invest 2008, 38:945-952.
25. Sorror M.L., Sandmaier B.M., Storer B.E., et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007, 20:4246-4254.
26. Zohren F., Czibere A., Bruns I., et al. Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia. Bone Marrow Transplant 2009, 44:785-792.
27. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
28. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
29. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 2005, 11:945-956.
30. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
31. Czibere A., Bruns I., Kröger N., et al. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 2010, 45:872-876.
32. Lübbert M., Bertz H., Wäsch R., et al. Efficacy of a 3-day, low dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant 2010, 45:627-632.
33. Jurado M., Deeg H.J., Storer B., et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant 2002, 8:161-169.
34. Runde V., de Witte T., Arnold C., et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998, 21:255-261.
35. Ossenkoppele G.J., van der Holt B., Verhoef G.E., et al. A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group. Leukemia 1999, 13:1207-1213.
36. Yakoub-Agha I., de La Salmonière P., Ribaud P., et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 2000, 18:963-971.
37. Itzykson R., Fenaux P. Optimal sequencing of treatments for patients with myelodysplastic syndromes. Curr Opin Hematol 2009, 16:77-83.
38. Warlick E.D., Cioc A., Defor T., et al. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant 2009, 15:30-38.
39. Oran B., Giralt S., Saliba R., et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 2007, 13:454-462.